InMed Pharmaceuticals (INM) Total Current Liabilities (2020 - 2026)

InMed Pharmaceuticals has reported Total Current Liabilities for 7 years, with the latest figure at $2.2 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 20.25% year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2026 stood at $2.2 million (up 20.25% YoY), and the FY2025 full-year result was $1.8 million, down 6.7% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $2.2 million, up from $1.5 million in the prior quarter.
• The five-year high for Total Current Liabilities was $4.1 million in Q1 2022, with the low at $1.3 million in Q3 2023.
• Historically, Total Current Liabilities has averaged $2.1 million across 5 years, with a median of $1.8 million in 2025.
• Annual changes were most pronounced in 2022 — Total Current Liabilities jumped 139.49% — and 2023, when it plunged 59.19%.
• InMed Pharmaceuticals' Total Current Liabilities stood at $2.4 million in 2022, then slumped by 30.0% to $1.7 million in 2023, then gained by 6.57% to $1.8 million in 2024, then decreased by 17.36% to $1.5 million in 2025, then surged by 49.41% to $2.2 million in 2026.
• The last three Total Current Liabilities figures came in at $2.2 million (Q1 2026), $1.5 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.